Early detection of head and neck cancer relapse by expression profiling of blood platelets and/or ctDNA analysis in plasma and oral rinses

Early detection of head and neck cancer relapse by expression profiling of blood platelets and/or ctDNA analysis in plasma and oral rinses - Early detection of head and neck cancer relapse

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49182

Enrollment

Registered

2020-11-20

Start date

2021-05-06

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hoofd-hals neoplasmata maligne head and neck cancer Squamous Cell Carcinoma of Head and Neck

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients must have an HNSCC, sufficient knowledge of the Dutch language to understand the meaning of the study as described in the patient information, signed informed consent for the study, be 18 years of age or older

Exclusion criteria

Exclusion criteria: Patiets who are scheduled for palliative treatment

Design outcomes

Primary

Measure	Time frame
Endpoints of the study are the accuracy of early detection of relapse by ctDNA and/or TEP analyses in head and neck cancer patients during follow-up.	—

Secondary

Measure	Time frame
- The median time frame of a positive test and the diagnosis of relapse - The presence of ctDNA in persurgery wound rinses as risk factor for relapse - Association of mutations in ctDNA with primary tumor and relapse - The role of intratumor genetic heterogeneity between primary tumor and relapse in relation to ctDNA detection	—

Countries

Netherlands

Outcome results